Sven Erickson
Chief Medical Officer
Medicine
Isofol Medical
Sweden
Biography
Sven Ericksson will lead the licensing and commercialization efforts of the company’s lead candidate Modufolin®. Prior to joining Isofol, Mr. Erickson served as Director of Medical Affairs in the Nordic region at PTC Therapeutics. Preceding his employment at PTC Therapeutics was his role as Product Search and Evaluation Manager at Medivir, a research-based pharmaceutical company with focus on oncology, managing in-licensing operations. Before joining Medivir in 2014, Mr. Erickson also held different positions at Novartis including Scandinavian Medical Head Critical Care. Mr. Eriksson is a PhD in Experimental Oncology from The Karolinska Institute, Sweden. Mr. Eriksson will be an important driving force behind the commercialization of Modufolin® and the company’s partnering efforts in preparations of a potential market approval. Sven joined Isofol Medical AB in August 2017. Position: Chief Medical Officer Holdings*: 0 shares and 0 warrants Contact: Email: sven.ericksson@isofolmedical.com Phone:(+46)722 006 090 *Own or related natural or legal person holding shares and other financial instruments in the company
Research Interest
Sven Ericksson will lead the licensing and commercialization efforts of the company’s lead candidate Modufolin®. Prior to joining Isofol, Mr. Erickson served as Director of Medical Affairs in the Nordic region at PTC Therapeutics. Preceding his employment at PTC Therapeutics was his role as Product Search and Evaluation Manager at Medivir, a research-based pharmaceutical company with focus on oncology, managing in-licensing operations. Before joining Medivir in 2014, Mr. Erickson also held different positions at Novartis including Scandinavian Medical Head Critical Care. Mr. Eriksson is a PhD in Experimental Oncology from The Karolinska Institute, Sweden. Mr. Eriksson will be an important driving force behind the commercialization of Modufolin® and the company’s partnering efforts in preparations of a potential market approval. Sven joined Isofol Medical AB in August 2017.
